Drug
Mepolizumab 100 MG [Nucala]
Mepolizumab 100 MG [Nucala] is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting1
unknown1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
recruiting133%
unknown133%
active_not_recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
recruiting
Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma
NCT05708300
active_not_recruiting
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
NCT04612556
unknownphase_4
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
NCT04228588
Clinical Trials (3)
Showing 3 of 3 trials
NCT05708300
Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma
NCT04612556
Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
NCT04228588Phase 4
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3